<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-90" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Central Line&#x02013;Associated Blood Stream Infections</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Haddadin</surname>
            <given-names>Yazan</given-names>
          </name>
          <aff>Jordan University of Science and Technology</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Annamaraju</surname>
            <given-names>Pavan</given-names>
          </name>
          <aff>Loma Linda University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Regunath</surname>
            <given-names>Hariharan</given-names>
          </name>
          <aff>University of Maryland - Baltimore Washington Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yazan Haddadin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pavan Annamaraju declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hariharan Regunath declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-90.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>A central line-associated bloodstream infection (CLABSI)&#x000a0;is&#x000a0;defined&#x000a0;as the recovery of a pathogen from a blood culture in a patient who had a central line at the time of infection or within 48 hours before the development of infection. Most cases are preventable with proper aseptic techniques, surveillance, and management strategies. This activity describes the evaluation and management of patients undergoing central line placement and highlights the role of the interprofessional team in improving care for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Determine&#x000a0;the pathophysiology of CLABSI.</p></list-item><list-item><p>Identify&#x000a0;key history and physical exam findings of patients with CLABSI.</p></list-item><list-item><p>Assess&#x000a0;the treatment options for CLABSI.</p></list-item><list-item><p>Communicate&#x000a0;modalities to improve care coordination among interprofessional team members in order to improve outcomes for patients affected by CLABSI.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=90&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=90">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-90.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>A central line-associated bloodstream infection (CLABSI)&#x000a0;is defined&#x000a0;as the recovery of a pathogen from a blood culture in a patient who had a central line at the time of infection or within 48 hours before the development of infection.&#x000a0;Of all the healthcare-associated infections, CLABSIs are associated with a high-cost burden, accounting for approximately $46,000 per case. Most cases&#x000a0;are preventable with proper aseptic techniques, surveillance, and management strategies.<xref ref-type="bibr" rid="article-90.r1">[1]</xref><xref ref-type="bibr" rid="article-90.r2">[2]</xref></p>
      </sec>
      <sec id="article-90.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Based on the National Healthcare Safety Network (NHSN) data from January 2006 to October 2007, the order of selected pathogens associated with causing CLABSI is as follows. Gram-positive organisms (coagulase-negative <bold>staphylococci</bold>,&#x000a0;34.1%;&#x000a0;<italic toggle="yes">enterococci</italic>,&#x000a0;16%; and&#x000a0;<italic toggle="yes">Staphylococcus aureus</italic>,&#x000a0;9.9%) are the most common, followed by gram-negatives (<italic toggle="yes">Klebsiella</italic>,&#x000a0;5.8%;&#x000a0;<italic toggle="yes">Enterobacter</italic>,&#x000a0;3.9%;&#x000a0;<italic toggle="yes">Pseudomonas</italic>,&#x000a0;3.1%;&#x000a0;<italic toggle="yes">E. coli</italic>,&#x000a0;2.7%;&#x000a0;<italic toggle="yes">Acinetobacter</italic>,&#x000a0;2.2%), <italic toggle="yes">Candida&#x000a0;</italic>species&#x000a0;(11.8%), and others (10.5%).<xref ref-type="bibr" rid="article-90.r3">[3]</xref><xref ref-type="bibr" rid="article-90.r4">[4]</xref></p>
        <p>Tunneled hemodialysis catheters are prone to CRBSIs. Approximately 40%&#x02013;80% of CRBSIs are caused by gram-positive organisms. Coagulase-negative <italic toggle="yes">Staphylococci, Staphylococcus aureus, </italic>and<italic toggle="yes"> Enterococcus</italic> are the most common organisms. Methicillin-resistant staphylococcus is frequently seen. Approximately 20% of gram-negative organisms cause 30% of infections and CRBSIs.<xref ref-type="bibr" rid="article-90.r5">[5]</xref></p>
      </sec>
      <sec id="article-90.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>CLABSIs&#x000a0;lead to prolonged hospital stays and increase healthcare costs&#x000a0;and mortality. An estimated 250,000 bloodstream infections occur annually, and most are related to the presence of&#x000a0;intravascular devices. In the United States, the CLABSI rate in intensive care units (ICU) is estimated to be 0.8 per 1000 central line days. International Nosocomial Infection Control Consortium (INICC) surveillance data from January 2010 through December 2015 (703 intensive care units in 50 countries) reported a CLABSI rate of 4.1 per 1000 central line days. Many central lines are found outside the ICUs. In&#x000a0;1 study, 55% of ICU and 24% of non-ICU patients had central lines. However, as more patients are located outside the ICU, 70% of hospitalized patients with central venous catheters were outside the ICU.<xref ref-type="bibr" rid="article-90.r6">[6]</xref>&#x000a0;In recent years, peripherally inserted central catheters (PICCs) have increased significantly, given some inherent&#x000a0;advantages these devices offer.<xref ref-type="bibr" rid="article-90.r7">[7]</xref>&#x000a0;Trained&#x000a0;clinical staff can place PICC lines at the bedside with ultrasound guidance, allowing quick central venous access in ICUs and general medical wards. Since PICCs are inserted in a peripheral arm vein with the tip advanced into a central vein (cavoatrial junction or the right atrium) by definition,&#x000a0;they&#x000a0;are central venous catheters (See <bold>Image.</bold> Central Venous Catheterization Body Access). The rates of CLABSI associated with PICCs are statistically similar to the conventional central venous catheters (CVCs) in the hospital setting.<xref ref-type="bibr" rid="article-90.r8">[8]</xref>&#x000a0;In a multicenter study of 27,289 patients, CLABSI outcomes were similar between the PICCs placed in the ICU and the general medical ward. However, the study was limited, with an overall low number of events.<xref ref-type="bibr" rid="article-90.r9">[9]</xref></p>
      </sec>
      <sec id="article-90.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Central lines are of&#x000a0;2 types: (1) Tunneled catheters are implanted surgically (by creating a subcutaneous track before entering the vein) into the internal jugular, subclavian, or femoral vein for long-term (weeks to months) use such as chemotherapy or hemodialysis and (2) Non-tunneled catheters, more commonly used. They are temporary central venous catheters inserted percutaneously and account for most CLABSIs. Within 7 to 10 days of central venous catheter placement, bacteria on the skin surface migrate along the external surface of the catheter from the skin exit site towards the intravascular space. Typically, tunneled catheters have a cuff that causes a fibrotic reaction around the catheter, creating&#x000a0;a barrier to bacterial migration). The absence of a tunnel (a subcutaneous tract) places non-tunneled catheters at higher risk for CLABSIs. CLABSIs that occur beyond&#x000a0;10 days are&#x000a0;usually caused by&#x000a0;contamination of the hub (intraluminal), typically from a health care provider's contaminated hands but rarely from a host and often due to a&#x000a0;breach of standard aseptic precautions to access the hub. Less common mechanisms include hematogenous seeding of bacteria from a contaminated infusate or another source.</p>
        <p>Chronic illnesses (hemodialysis, malignancy, gastrointestinal tract disorders, pulmonary hypertension), immune-suppressed states (organ transplant, diabetes mellitus), malnutrition, total parenteral nutrition, extremes of age, loss of skin integrity (burns), and prolonged hospitalization before line insertion are host factors that increase the risk of CLABSI.</p>
        <p>Femoral central venous catheters are associated with the highest risk of CLABSI, followed by internal jugular and subclavian catheters. Further, the catheter type, insertion conditions (emergent versus&#x000a0;elective, use of full barrier precautions versus limited), catheter care, and operator skill also influence the risk of CLABSI.</p>
        <p><italic toggle="yes">Pseudomonas</italic>&#x000a0;is commonly associated with&#x000a0;neutropenia, severe illness, or known prior colonization.&#x000a0;<italic toggle="yes">Candida</italic>&#x000a0;is associated with risk factors: femoral catheterization,&#x000a0;TPN, prolonged administration of broad-spectrum antibiotics, hematologic malignancy, or solid organ or hematopoietic stem cell transplantation. Certain bacteria such as staphylococci, <italic toggle="yes">Pseudomonas,</italic> and&#x000a0;<italic toggle="yes">Candida</italic>&#x000a0;produce extracellular polysaccharide [slime (biofilm)], which favors increased virulence, adherence to catheter surface, and resistance to antimicrobial therapy.<xref ref-type="bibr" rid="article-90.r10">[10]</xref></p>
      </sec>
      <sec id="article-90.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clinical manifestations vary depending on the severity of the illness. Fever and chills are the most common manifestations. Still, they may be&#x000a0;masked if the patient is immunocompromised or at extremes of an age where atypical presentations of sepsis occur (altered mental status, hypotension, lethargy, fatigue). Exit site examination to look for signs of inflammation&#x000a0;of tunneled catheters with inspection and palpation of the subcutaneous track is essential. Patients may report pain, swelling, or discharge from the exit site and redness surrounding or along the subcutaneous track when exit site or tunnel infections are present. For long-term catheters, difficulty drawing blood or poor flow are risk factors and manifestations of CLABSI.&#x000a0;</p>
      </sec>
      <sec id="article-90.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In addition to the clinical exam, lab investigations are essential for diagnosis and management. Blood culture is the most crucial step towards diagnosis, in addition to completing blood count, serum electrolytes, and renal and liver function tests, which are necessary to assess for severity and co-morbidities. In suspected cases, paired blood cultures (one from the central line and peripheral vein) must be drawn and labeled accordingly before being sent to the lab. In the case of poor peripheral access or when unable to obtain a peripheral sample,&#x000a0;2 or more samples must be drawn from different lumens of a multi-lumen central line. The following definitions help in arriving at a diagnosis:</p>
        <p><bold><italic toggle="yes">Catheter-related bloodstream infection (CRBSI) -&#x000a0;</italic></bold><bold><italic toggle="yes">Infectious Diseases Society of America (IDSA)&#x000a0;</italic>definition:</bold> Catheter-related bloodstream infection (CRBSI) is the preferred term used by IDSA. The definite diagnosis of CRBSI requires&#x000a0;1 of the following: Isolation of the same pathogen from a quantitative blood culture drawn through the central line&#x000a0;and from a peripheral vein with the single bacterial colony count at least threefold higher in the sample from the central line as compared to that obtained from a peripheral vein (or) same organism recovered from percutaneous blood culture and quantitative (&#x0003e;15 colony-forming units) culture of the catheter tip (or) a&#x000a0;shorter time to positive culture (&#x0003e;2 hours earlier) in the central line sample&#x000a0;than the peripheral sample (differential time to positivity [&#x000a0;DTP&#x000a0;]).<xref ref-type="bibr" rid="article-90.r11">[11]</xref></p>
        <p><bold><italic toggle="yes">CLABSI&#x000a0;-&#x000a0;Centers for Disease Control and Prevention (CDC) definition</italic></bold>: CLABSI is a surveillance definition used by the CDC and defined&#x000a0;as the recovery of a pathogen from a blood culture (a single blood culture for an organism not commonly present on the skin and&#x000a0;2 or more blood cultures for organism commonly present on the skin) in a patient who had a central line at the time of infection or within 48 hours before the development of infection. The infection cannot be related to any other infection the patient might have and must not have been present or incubating when the patient was admitted to the facility.<xref ref-type="bibr" rid="article-90.r4">[4]</xref></p>
        <p>In the case of tunneled catheters, the accepted definitions for exit site and tunnel infections are&#x000a0;as follows:</p>
        <p><bold>Exit site infection:</bold> Signs of inflammation confined to an area (typically &#x0003c; 2 cm) surrounding the catheter exit site and the presence of&#x000a0;exudate that proves to be culture-positive.</p>
        <p><bold>Tunnel infection:</bold><italic toggle="yes"><bold>&#x000a0;</bold></italic>Inflammation extending beyond 2 cm from the exit site (along with the track or cephalad towards the vein entry site or extending beyond the cuff), typically associated with pain and tenderness along the subcutaneous track and culture-positive exudate at the exit site that may not be seen unless expressed by palpation.&#x000a0;</p>
      </sec>
      <sec id="article-90.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>When CLABSI is suspected, empiric therapy should be based on the most likely organism, host factors, and the overall clinical picture. While awaiting cultures, empiric treatment should be instituted promptly. In general, coverage for common gram-positive and gram-negative organisms is necessary. The&#x000a0;local prevalence and antimicrobial susceptibility patterns in institutional antibiograms should be considered. The following are some&#x000a0;considerations.</p>
        <list list-type="order">
          <list-item>
            <p>Parenteral vancomycin if methicillin-resistant staphylococci&#x000a0;(MRSA)&#x000a0;is prevalent. Otherwise, parenteral anti-staphylococcal penicillin or cephalosporins such as nafcillin or cefazolin would suffice. If MRSA isolates exhibit a minimum inhibitory concentration of &#x0003e; 2 mg/mL for vancomycin or, in the case of vancomycin-resistant enterococci (VRE), daptomycin is the drug of choice.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>The antibiotic choice for gram-negative coverage should be based on the risk of pseudomonal infection and local susceptibility patterns. If the risk of Pseudomonas is low, then a third-generation cephalosporin such as ceftriaxone is appropriate. In patients with a critical illness or high risk for resistant organisms, a combination of a beta-lactam (lactamase inhibitor) and an aminoglycoside is preferred - Cefepime or carbapenem with or without an aminoglycoside. Agents against <italic toggle="yes">Pseudomonas aeruginosa</italic>&#x000a0;are required&#x000a0;for neutropenia, severe illness, or known prior colonization.</p>
          </list-item>
          <list-item>
            <p>Echinocandins (micafungin, caspofungin, anidulafungin) are preferred agents for suspected candidemia if azole resistance is suspected (prior azole use or prevalent nonalbicans candida such as <italic toggle="yes">C.glabrata</italic> or <italic toggle="yes">C.krusei</italic>). Otherwise, intravenous fluconazole would suffice. Antifungal therapy must be considered in femoral catheterization, TPN, prolonged administration of broad-spectrum antibiotics, hematologic malignancy, or solid organ or bone marrow transplant recipients.</p>
          </list-item>
        </list>
        <p>Once antimicrobial susceptibility results are available, de-escalation to specific and appropriate therapy is recommended.&#x000a0;If blood cultures have no growth, the need for further empiric antibiotic treatment should be reassessed. Suppose unexplained fever or sepsis persisted in a patient with a short-term central&#x000a0;venous or arterial catheter and paired peripheral venipuncture and catheter blood cultures have failed to identify CLABSI. In that case, the catheter should be removed,&#x000a0;and the tip should be sent for culture.&#x000a0;</p>
        <p>All non-tunneled catheters causing CLABSI should be removed promptly, sometimes even before it is proven with the above criteria when clinical suspicion is high.&#x000a0;Only for long-term catheters,&#x000a0;salvage (systemic therapy coupled with antimicrobial lock [heparin + high concentration of antimicrobial agent that is selected based on susceptibility results]) can be attempted in limited instances such as:</p>
        <list list-type="order">
          <list-item>
            <p>Uncomplicated CLABSI is caused by organisms other than <italic toggle="yes">Staphylococcus </italic><italic toggle="yes">aureus</italic>, <italic toggle="yes">Pseudomonas aeruginosa</italic>, Bacillus spp, Micrococcus species, Propionibacteria, fungi, or mycobacteria.</p>
          </list-item>
          <list-item>
            <p>The patients with limited vascular access sites or the ones who are solely dependent on central access for survival.</p>
          </list-item>
        </list>
        <p>In the case of tunneled hemodialysis catheters, uncomplicated exit site infections can be treated with short-course topical or systemic antimicrobials. All tunnel infections require catheter removal due to a high risk of CLABSI. Additional indications for removal of CLABSI from hemodialysis access include:</p>
        <list list-type="order">
          <list-item>
            <p>Persistent symptoms &#x0003e; 36 hours or severe sepsis, hemodynamic instability(shock), and metastatic infection.</p>
          </list-item>
          <list-item>
            <p>Blood cultures that remain positive &#x0003e; 72 hours of appropriate antimicrobial therapy.</p>
          </list-item>
          <list-item>
            <p>Difficulty in clearing organisms (<italic toggle="yes">S. aureus, Pseudomonas,</italic> or fungi).</p>
          </list-item>
          <list-item>
            <p>Recurrence of uncomplicated CLABSI (any non-virulent organism) when salvaged for difficult access.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Duration of therapy</bold>: For patients with uncomplicated CRBSI (eg, no endocarditis or metastatic infection), in the absence of risk factors for hematogenous spread (eg, hardware, immunosuppression) and negative blood cultures 72 hours of catheter removal, following approach for intravenous antimicrobial therapy&#x000a0;is recommended:</p>
        <list list-type="order">
          <list-item>
            <p><italic toggle="yes">S. aureus -&#x000a0;</italic>14 days in the absence of endocarditis</p>
          </list-item>
          <list-item>
            <p>Coagulase-negative staphylococci - 7 days</p>
          </list-item>
          <list-item>
            <p>Enterococci and gram-negative bacilli - 10 to 14 days</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Candida</italic>&#x000a0;- 14 days in the absence of retinitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-90.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for central line-associated bloodstream infections&#x000a0;include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Exit site infections</p>
          </list-item>
          <list-item>
            <p>Phlebitis</p>
          </list-item>
          <list-item>
            <p>Pocket infections</p>
          </list-item>
          <list-item>
            <p>Sepsis</p>
          </list-item>
          <list-item>
            <p>Tunnel infections</p>
          </list-item>
          <list-item>
            <p>Urinary tract infection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-90.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Prevention Guidelines During Insertion</bold>
</p>
        <p>Recent data reveal no difference in the infection rate based on the insertion catheter site. The following are some&#x000a0;key components of a prevention program, abstracted from an extensive list provided by the CDC and IDSA.<xref ref-type="bibr" rid="article-90.r12">[12]</xref><xref ref-type="bibr" rid="article-90.r13">[13]</xref><xref ref-type="bibr" rid="article-90.r10">[10]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Hand hygiene by washing hands with soap, water, or alcohol-based gels or foams. Gloves do not prevent the need for hand hygiene.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>A strict aseptic technique using maximal sterile barrier precautions, including a full-body drape when inserting central venous catheters.</p>
          </list-item>
          <list-item>
            <p>Use 2% chlorhexidine skin preparations for disinfecting/ cleaning skin before insertion.</p>
          </list-item>
          <list-item>
            <p>Ultrasound guidance by an experienced provider for placement to circumvent mechanical complications and reduce the number of attempts.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Avoid the&#x000a0;femoral vein for central line placement, and prefer the subclavian vein when possible for non-tunneled catheters.</p>
          </list-item>
          <list-item>
            <p>Promptly remove&#x000a0;any central line that is no longer required.</p>
          </list-item>
          <list-item>
            <p>Replace central lines placed during an emergency (asepsis not assured) as soon as possible or within 48 hours.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Use a checklist.</p>
          </list-item>
        </list>
        <p>
<bold>Prevention Guidelines During Maintenance</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Disinfect the catheter hubs, injection ports, and connections before accessing the line.</p>
          </list-item>
          <list-item>
            <p>Replace administration sets other than sets used for lipids or blood products every 96 hours.</p>
          </list-item>
          <list-item>
            <p>Assess&#x000a0;the need for the central line daily.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-90.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Central line-associated bloodstream infection (CLABSI) is a prevalent problem in the intensive care unit. These infections are associated with over 28,000 deaths yearly and cost over $2 billion. Only through best practices, protocols, checklists, and establishing a culture of patient safety in healthcare institutions can CLABSI be reduced to zero.<xref ref-type="bibr" rid="article-90.r14">[14]</xref> One of the significant reasons for central line removal is an infection or suspicion. This clinical practice leads to prolonged hospital stays and increased procedures and complication rates.</p>
        <p>One of the challenges with central lines is the variety of catheter types inserted by diverse staff. In many hospitals, central lines are inserted by specialists, including anesthesiologists, surgeons, emergency room physicians, radiologists, and critical care physicians.<xref ref-type="bibr" rid="article-90.r15">[15]</xref>&#x000a0;PICC lines are often inserted by trained&#x000a0;clinical staff. This heterogeneity has resulted in varied outcomes, but infections remain a common problem in almost every study.</p>
        <p>
<bold>Evidence-</bold>
<bold>Based Medicine</bold>
</p>
        <p>Over the years, many guidelines have been established; some hospitals have a policy that for long-term access, the line can only be inserted by a&#x000a0;dedicated team that&#x000a0;consists of the surgeon, nurses, and a pharmacist who monitors the patient. In addition, when administering TPN,&#x000a0;1 port is dedicated to nutrition. Plus, in some units, only&#x000a0;clinicians with training in central lines can infuse medications and other solutions. Evidence-based guidelines show that adhering to protocols can reduce the rate of CLABSI. However, audits of clinicians&#x000a0;who insert the central lines and monitor the lines for infections are vital to ensure compliance.<xref ref-type="bibr" rid="article-90.r10">[10]</xref></p>
      </sec>
      <sec id="article-90.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=90&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=90">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/central-line-associated-blood-stream-infections/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=90">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/90/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=90">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-90.s13">
        <fig id="article-90.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Central Venous Catheterization Body Access. This image shows different access sites in the body for central venous catheterization. Contributed by A Tariq, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medical__new-01" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-90.s14">
        <title>References</title>
        <ref id="article-90.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hallam</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rajgopal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Establishing catheter-related bloodstream infection surveillance to drive improvement.</article-title>
            <source>J Infect Prev</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>160</fpage>
            <page-range>160-166</page-range>
            <pub-id pub-id-type="pmid">30013620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aloush</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Alsaraireh</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Nurses' compliance with central line associated blood stream infection prevention guidelines.</article-title>
            <source>Saudi Med J</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>273</fpage>
            <page-range>273-279</page-range>
            <pub-id pub-id-type="pmid">29543306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atilla</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Do&#x0011f;anay</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Kefeli &#x000c7;elik</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Demira&#x0011f;</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>S Kili&#x000e7;</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Central line-associated blood stream infections: characteristics and risk factors for mortality over a 5.5-year period.</article-title>
            <source>Turk J Med Sci</source>
            <year>2017</year>
            <month>Apr</month>
            <day>18</day>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>646</fpage>
            <page-range>646-652</page-range>
            <pub-id pub-id-type="pmid">28425261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wright</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Decker</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Allen-Bridson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hebden</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Leaptrot</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Healthcare-associated infections studies project: An American Journal of Infection Control and National Healthcare Safety Network data quality collaboration: Location mapping.</article-title>
            <source>Am J Infect Control</source>
            <year>2018</year>
            <month>May</month>
            <volume>46</volume>
            <issue>5</issue>
            <fpage>577</fpage>
            <page-range>577-578</page-range>
            <pub-id pub-id-type="pmid">29449023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrington</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Allon</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Management of the Hemodialysis Patient with Catheter-Related Bloodstream Infection.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>05</day>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>611</fpage>
            <page-range>611-613</page-range>
            <pub-id pub-id-type="pmid">30837242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziegler</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Pellegrini</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Safdar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Attributable mortality of central line associated bloodstream infection: systematic review and meta-analysis.</article-title>
            <source>Infection</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-36</page-range>
            <pub-id pub-id-type="pmid">25331552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Moineddin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mahant</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Filipescu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amaral</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Peripherally inserted central catheters: use at a tertiary care pediatric center.</article-title>
            <source>J Vasc Interv Radiol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>9</issue>
            <fpage>1323</fpage>
            <page-range>1323-31</page-range>
            <pub-id pub-id-type="pmid">23876551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chopra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>O'Horo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Maki</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Safdar</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>The risk of bloodstream infection associated with peripherally inserted central catheters compared with central venous catheters in adults: a systematic review and meta-analysis.</article-title>
            <source>Infect Control Hosp Epidemiol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>34</volume>
            <issue>9</issue>
            <fpage>908</fpage>
            <page-range>908-18</page-range>
            <pub-id pub-id-type="pmid">23917904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Govindan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Flanders</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Peripherally Inserted Central Catheters in the ICU: A Retrospective Study of Adult Medical Patients in 52 Hospitals.</article-title>
            <source>Crit Care Med</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>e1136</fpage>
            <page-range>e1136-e1144</page-range>
            <pub-id pub-id-type="pmid">30247241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bell</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>O'Grady</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>Prevention of Central Line-Associated Bloodstream Infections.</article-title>
            <source>Infect Dis Clin North Am</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>551</fpage>
            <page-range>551-559</page-range>
            <pub-id pub-id-type="pmid">28687213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lissauer</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Leekha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Preas</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Thom</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for central line-associated bloodstream infections in the era of best practice.</article-title>
            <source>J Trauma Acute Care Surg</source>
            <year>2012</year>
            <month>May</month>
            <volume>72</volume>
            <issue>5</issue>
            <fpage>1174</fpage>
            <page-range>1174-80</page-range>
            <pub-id pub-id-type="pmid">22673242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>YG</given-names>
              </name>
            </person-group>
            <article-title>Effect of Central Line Bundle Compliance on Central Line-Associated Bloodstream Infections.</article-title>
            <source>Yonsei Med J</source>
            <year>2018</year>
            <month>May</month>
            <volume>59</volume>
            <issue>3</issue>
            <fpage>376</fpage>
            <page-range>376-382</page-range>
            <pub-id pub-id-type="pmid">29611399</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Norris</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Kablaoui</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brilhart</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Bookstaver</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of antimicrobial lock therapy for prevention of central-line-associated bloodstream infections in adult and pediatric cancer patients.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>308</fpage>
            <page-range>308-317</page-range>
            <pub-id pub-id-type="pmid">28689878</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sagana</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hyzy</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Achieving zero central line-associated bloodstream infection rates in your intensive care unit.</article-title>
            <source>Crit Care Clin</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>29</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-9</page-range>
            <pub-id pub-id-type="pmid">23182523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-90.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takashima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schults</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mihala</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ullman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Complication and Failures of Central Vascular Access Device in Adult Critical Care Settings.</article-title>
            <source>Crit Care Med</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>1998</fpage>
            <page-range>1998-2009</page-range>
            <pub-id pub-id-type="pmid">30095499</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
